Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX
08:16pm, Friday, 20'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
09:54pm, Thursday, 19'th Mar 2026
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are a
What's Going On With Aldeyra Therapeutics Stock On Thursday?
09:01am, Thursday, 19'th Mar 2026
Since Tuesday, the company's stock has slumped by around 67%.
Aldeyra Therapeutics Touted Reproxalap's Regulatory Path While FDA Ultimately Found Insufficient Efficacy NEW YORK, March 18, 2026 /PRNewswire/ -- Investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX)
12:34pm, Wednesday, 18'th Mar 2026
New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDA
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
12:10pm, Wednesday, 18'th Mar 2026
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
Aldeyra Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow $ALDX Shareholders to Recover Losses
10:03am, Wednesday, 18'th Mar 2026
Boston, Massachusetts--(Newsfile Corp. - March 18, 2026) - Block & Leviton is investigating Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential securities law violations. Investors who have lost m
San Diego, California--(Newsfile Corp. - March 17, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focus
Block & Leviton is investigating Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) for potential securities law violations. ALDX investors should contact the firm.
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focuses on Aldeyra
US FDA declines to approve Aldeyra's drug for eye disorder
08:36am, Tuesday, 17'th Mar 2026
The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
10:41am, Thursday, 26'th Feb 2026
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?
10:56am, Thursday, 19'th Feb 2026
The consensus price target hints at a 79.3% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
07:01am, Wednesday, 18'th Feb 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
